# Cagrilintide

> Long-acting amylin analog studied alongside semaglutide as CagriSema.

- Class: Metabolic
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/cagrilintide

## Overview

Cagrilintide is a 37-amino-acid acylated amylin analog with affinity at all five amylin receptor subtypes. Investigated by Novo Nordisk both as monotherapy and in combination with semaglutide (CagriSema).

Cagrilintide is a long-acting, acylated analog of amylin — the pancreatic hormone co-secreted with insulin that signals satiety and slows gastric emptying. It binds across the amylin and calcitonin receptor subtypes and carries a fatty-acid chain that supports once-weekly dosing.

Developed by Novo Nordisk, it is investigational and studied both on its own and in a fixed combination with semaglutide known as CagriSema, where the amylin and GLP-1 pathways are paired for additive weight effect.

## Mechanism

Amylin and calcitonin receptor agonism → satiety, slowed gastric emptying.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C194H312N54O59S2 |
| Molecular weight | 4409.2 Da |
| CAS number | 1415456-99-3 |
| PubChem CID | [171397054](https://pubchem.ncbi.nlm.nih.gov/compound/171397054) |

## Research areas

Studied in: Obesity, Combination metabolic therapy.

Guides on this site:

- [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss.

## Key research

- Satiety signaling — amylin-receptor agonism studied for appetite suppression and slowed gastric emptying.
- Combination therapy — investigated with semaglutide (CagriSema) for additive weight reduction.
- Obesity endpoints — Phase 2 trials reported meaningful mean weight loss alone and in combination.
- Half-life engineering — acylation supports a once-weekly profile.
- Investigational status — not FDA-approved.

## FAQs

### What is cagrilintide?

Cagrilintide is an investigational long-acting amylin analog studied for weight management, both alone and combined with semaglutide (CagriSema).

### What is CagriSema?

CagriSema is the investigational fixed combination of cagrilintide (amylin) and semaglutide (GLP-1), pairing two appetite pathways for additive effect.

### How does amylin differ from GLP-1?

Both promote satiety, but amylin acts through amylin and calcitonin receptors while GLP-1 acts through the GLP-1 receptor; combining them is studied for complementary effects.

### Is cagrilintide approved?

No — it is investigational. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning Cagrilintide, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels](https://clinicaltrials.gov/study/NCT05669755) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT05669755
- [A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight](https://clinicaltrials.gov/study/NCT07253285) — RECRUITING · PHASE3 · NCT07253285
- [A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight](https://clinicaltrials.gov/study/NCT05567796) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT05567796
- [A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both](https://clinicaltrials.gov/study/NCT06534411) — COMPLETED · PHASE3 · NCT06534411
- [A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight](https://clinicaltrials.gov/study/NCT07357766) — WITHDRAWN · PHASE3 · NCT07357766
- [A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes](https://clinicaltrials.gov/study/NCT07357740) — WITHDRAWN · PHASE2 · NCT07357740

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/cagrilintide
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.